CA2216623C - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections Download PDF

Info

Publication number
CA2216623C
CA2216623C CA002216623A CA2216623A CA2216623C CA 2216623 C CA2216623 C CA 2216623C CA 002216623 A CA002216623 A CA 002216623A CA 2216623 A CA2216623 A CA 2216623A CA 2216623 C CA2216623 C CA 2216623C
Authority
CA
Canada
Prior art keywords
fumagillol
intestinal infections
preparation
fumagillin
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002216623A
Other languages
English (en)
French (fr)
Other versions
CA2216623A1 (en
Inventor
Jean-Michel Molina
Francis Derouin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Assistance Publique - Hôpitaux de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Assistance Publique - Hôpitaux de Paris filed Critical Sanofi Synthelabo SA
Publication of CA2216623A1 publication Critical patent/CA2216623A1/en
Application granted granted Critical
Publication of CA2216623C publication Critical patent/CA2216623C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002216623A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections Expired - Lifetime CA2216623C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR95/03549 1995-03-27
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
CA2216623A1 CA2216623A1 (en) 1996-10-03
CA2216623C true CA2216623C (en) 2005-05-31

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002216623A Expired - Lifetime CA2216623C (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections

Country Status (25)

Country Link
US (1) US5900431A (enExample)
EP (1) EP0817626B1 (enExample)
JP (1) JP3260378B2 (enExample)
KR (1) KR100286920B1 (enExample)
CN (1) CN1072485C (enExample)
AP (1) AP646A (enExample)
AT (1) ATE172641T1 (enExample)
AU (1) AU706161B2 (enExample)
CA (1) CA2216623C (enExample)
CZ (1) CZ286821B6 (enExample)
DE (1) DE69600879T2 (enExample)
DK (1) DK0817626T3 (enExample)
EA (1) EA000150B1 (enExample)
ES (1) ES2128846T3 (enExample)
FR (1) FR06C0014I2 (enExample)
HU (1) HU224028B1 (enExample)
IS (1) IS2048B (enExample)
NO (1) NO315968B1 (enExample)
NZ (1) NZ304906A (enExample)
OA (1) OA10515A (enExample)
PL (1) PL183378B1 (enExample)
SK (1) SK283883B6 (enExample)
TR (1) TR199701048T1 (enExample)
UA (1) UA41446C2 (enExample)
WO (1) WO1996030010A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ATE361757T1 (de) * 1999-02-26 2007-06-15 Sanofi Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
BRPI0820229A2 (pt) * 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
EP2317845A4 (en) * 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
EP0541716A1 (en) * 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en) 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
SK130797A3 (en) 1998-03-04
CN1179715A (zh) 1998-04-22
FR06C0014I1 (enExample) 2006-11-17
EA199700267A1 (ru) 1998-04-30
JP3260378B2 (ja) 2002-02-25
ES2128846T3 (es) 1999-05-16
CN1072485C (zh) 2001-10-10
EP0817626A2 (fr) 1998-01-14
CZ304997A3 (en) 1997-12-17
HUP9801220A2 (hu) 1999-09-28
UA41446C2 (uk) 2001-09-17
CA2216623A1 (en) 1996-10-03
AU5278696A (en) 1996-10-16
ATE172641T1 (de) 1998-11-15
KR100286920B1 (ko) 2001-04-16
NO974466D0 (no) 1997-09-26
FR06C0014I2 (enExample) 2006-12-29
NO974466L (no) 1997-09-26
AP646A (en) 1998-04-27
JPH11506421A (ja) 1999-06-08
NZ304906A (en) 1999-06-29
EP0817626B1 (fr) 1998-10-28
HUP9801220A3 (en) 2001-10-29
WO1996030010A3 (fr) 1996-11-28
MX9707150A (es) 1998-07-31
NO315968B1 (no) 2003-11-24
DE69600879T2 (de) 1999-06-02
AU706161B2 (en) 1999-06-10
CZ286821B6 (en) 2000-07-12
IS4557A (is) 1997-09-11
US5900431A (en) 1999-05-04
PL322470A1 (en) 1998-02-02
PL183378B1 (pl) 2002-06-28
TR199701048T1 (xx) 1998-01-21
WO1996030010A2 (fr) 1996-10-03
SK283883B6 (sk) 2004-04-06
IS2048B (is) 2005-09-15
EA000150B1 (ru) 1998-10-29
DE69600879D1 (de) 1998-12-03
OA10515A (fr) 2002-04-24
DK0817626T3 (da) 1999-07-12
KR19980703271A (ko) 1998-10-15
AP9701092A0 (en) 1997-10-31
HU224028B1 (hu) 2005-05-30

Similar Documents

Publication Publication Date Title
US5900431A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
JPH0621079B2 (ja) 下痢止め組成物及びその用途
CA1243605A (en) Antidiarrheal compositions and use thereof
KR20000016266A (ko) 비수용성 결장 하제 조성물_
US5348744A (en) Antidiarrheal compositions containing loperamide hydrochloride and a saccharide
US5837256A (en) Method for treatment of Lupus nephritis
EP0786993A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
EP0190851B1 (en) Improved antiinflammatory composition
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
CA2255640A1 (en) Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
US20230144875A1 (en) Highly purified eicosapentaenoic acid, as free fatty acid for treatment of coronaviruses and specifically novel coronavirus-19 (covid-19)
EP0555302A1 (en) Method of treating demyelinating disease
US7485642B2 (en) Method for treating septic shock
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
JPS63145233A (ja) 白内障治療剤
JPH0132804B2 (enExample)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
EP0118968A1 (en) Use of avilamycin to control swine dysentery
WO2020242410A1 (en) Pharmaceutical compositions comprising ursodeoxycholic acid as active substance
FR2566664A1 (fr) Composition utile au traitement de la diarrhee contenant du dextromethorphan
WO1996011679A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160329